These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36991239)

  • 1. On a 5-year-old girl with multiple sclerosis treated with natalizumab.
    Sotgiu S; Nieddu A; Pruna D; Madrau A; Zarbo IR; Carta A
    Neurol Sci; 2023 Aug; 44(8):2963-2965. PubMed ID: 36991239
    [No Abstract]   [Full Text] [Related]  

  • 2. Concurrent management of multiple sclerosis and natalizumab-induced hepatitis with ofatumumab: a case report.
    Haggiag S; Giannelli V; Prosperini L; Cruciani A; Baiocchini A; Ruggieri S; Pellicelli A; Gasperini C; Tortorella C
    Neurol Sci; 2024 Oct; 45(10):5087-5089. PubMed ID: 38861049
    [No Abstract]   [Full Text] [Related]  

  • 3. Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.
    Shirani A; Stüve O
    J Immunol; 2017 Feb; 198(4):1381-1386. PubMed ID: 28167648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    Koch M
    J Neurol Neurosurg Psychiatry; 2024 Apr; 95(5):391. PubMed ID: 37963724
    [No Abstract]   [Full Text] [Related]  

  • 5. Fingerprick blood samples to measure serum natalizumab concentrations.
    Toorop AA; Steenhuis M; Loeff FC; Weijers SS; Killestein J; Rispens T; Kempen ZLV
    Mult Scler; 2023 Mar; 29(3):457-460. PubMed ID: 36448735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
    Wiebenga OT; Schoonheim MM; Hulst HE; Nagtegaal GJ; Strijbis EM; Steenwijk MD; Polman CH; Pouwels PJ; Barkhof F; Geurts JJ
    AJNR Am J Neuroradiol; 2016 Jun; 37(6):1030-7. PubMed ID: 26965463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three cases of herpes zoster radiculitis in MS patients treated with natalizumab.
    Yamout BI; Abou Zeid N; Taha AJ; Zeineddine MM; Khoury SJ
    Mult Scler Relat Disord; 2016 Sep; 9():122-4. PubMed ID: 27645358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
    Kalincik T; Brown JWL; Robertson N; Willis M; Scolding N; Rice CM; Wilkins A; Pearson O; Ziemssen T; Hutchinson M; McGuigan C; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Alroughani R; Pucci E; Sola P; Hupperts R; Lechner-Scott J; Terzi M; Van Pesch V; Rozsa C; Grand'Maison F; Boz C; Granella F; Slee M; Spitaleri D; Olascoaga J; Bergamaschi R; Verheul F; Vucic S; McCombe P; Hodgkinson S; Sanchez-Menoyo JL; Ampapa R; Simo M; Csepany T; Ramo C; Cristiano E; Barnett M; Butzkueven H; Coles A;
    Lancet Neurol; 2017 Apr; 16(4):271-281. PubMed ID: 28209331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and radiological control of highly active relapsing-remitting multiple sclerosis with first-line natalizumab.
    Meca-Lallana JE; Carreón-Guarnizo E; Hernández-Clares R; García-Molina E; Díaz-Pérez J; Leon-Hernández A; Zamarro-Parra J; Martín-Fernández JJ
    Neurodegener Dis Manag; 2017 Jun; 7(3):175-181. PubMed ID: 28592169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab.
    Fiander MDJ; Bhan V; Stewart SA; Parks NE
    Can J Neurol Sci; 2019 Jul; 46(4):455-458. PubMed ID: 31113500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent skin infections associated with natalizumab treatment.
    Oliveira DS; Castro AR; Ruano L
    Neurol Sci; 2023 Mar; 44(3):1093-1095. PubMed ID: 36331655
    [No Abstract]   [Full Text] [Related]  

  • 12. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
    Boz C; Ozakbas S; Terzi M; Karabudak R; Sevim S; Turkoglu R; Soysal A; Balcı BP; Efendi H; Turan ÖF; Yüceyar N; Yetkin MF; Karahan SZ; Demirkıran M; Guler S; Agan K; Kıylıoğlu N; Baba C; Tuncer A; Köseoğlu M
    Neurol Sci; 2023 Jun; 44(6):2121-2129. PubMed ID: 36689010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.
    Alharbi MA; Aldosari F; Althobaiti AH; Abdullah FM; Aljarallah S; Alkhawajah NM; Alanazi M; AlRuthia Y
    BMC Health Serv Res; 2023 May; 23(1):552. PubMed ID: 37237257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Kropshofer H; Häring DA; Kappos L; Leppert D; Kuhle J
    Neurology; 2022 Mar; 98(11):470-471. PubMed ID: 35288475
    [No Abstract]   [Full Text] [Related]  

  • 15. Author Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Bridel C; Killestein J; Teunissen C
    Neurology; 2022 Mar; 98(11):471. PubMed ID: 35288476
    [No Abstract]   [Full Text] [Related]  

  • 16. Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.
    Federle L; Puthenparampil M; Stenta G; Paolo G; Francesco P
    Mult Scler Relat Disord; 2019 May; 30():262-264. PubMed ID: 30851640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab for multiple sclerosis: the dilemma of NOVA.
    Hellwig K
    Lancet Neurol; 2022 Jul; 21(7):579-581. PubMed ID: 35483388
    [No Abstract]   [Full Text] [Related]  

  • 18. Progressive multifocal leukoencephalopathy in the era of new disease-modifying treatments for multiple sclerosis.
    Filippi-Arriaga F; Riera-Arnau J; Rodríguez-Acevedo B; Bosch Ferrer M
    Med Clin (Barc); 2021 May; 156(10):509-514. PubMed ID: 33431183
    [No Abstract]   [Full Text] [Related]  

  • 19. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.
    Puig-Casadevall M; Álvarez-Bravo G; Varela AQ; Robles-Cedeño R; Sànchez Cirera L; Miguela A; Laguillo G; Montalban X; Hauser SL; Ramió-Torrentà L
    Eur J Neurol; 2023 Oct; 30(10):3357-3361. PubMed ID: 37485841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab subcutaneous injection for the treatment of relapsing multiple sclerosis patients: A new delivery route.
    López PA; Alonso R; Silva B; Carnero Contentti E
    Mult Scler Relat Disord; 2021 Oct; 55():103179. PubMed ID: 34339931
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.